Addressing Testing Implementation in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Jason Mouabbi and Dr. Seth Wander discuss practical considerations for integrating molecular testing approaches into routine care for patients with HR-positive, HER2-negative advanced breast cancer. The experts examine how ctDNA testing may help identify emerging resistance mechanisms, including ESR1 mutations, and provide additional information about tumor evolution. Dr. Wander highlights the need to balance the clinical utility of genomic testing with real-world factors such as accessibility, cost, and implementation challenges. The discussion explores the potential role of focused biomarker panels compared with broader genomic profiling approaches, emphasizing the advantages and limitations of each strategy. Dr. Mouabbi and Dr. Wander also discuss the continued importance of comprehensive molecular data in advancing research and identifying future mechanisms of resistance. The conversation highlights the ongoing effort to optimize practical, efficient, and personalized testing strategies for patients with HR-positive, HER2-negative advanced breast cancer.